Phase III trial data support current standard 12-month adjuvant Trastuzumab for HER2-positive breast cancer

Official press release from San Antonio Breast Cancer Symposium 2017.

Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, presented at the 2017 San Antonio Breast Cancer Symposium.

The study, however, found no substantial difference in the secondary endpoints of distant disease-free survival (DDFS) and overall survival (OS) between the 12-month trastuzumab arm and the nine-week trastuzumab arm.

 

 

The choice for one-year duration of trastuzumab administration in patients with HER2-positive breast cancer was arbitrary, and not based on research data. The current standard treatment is lengthy, costly, and occasionally associated with cardiac adverse events. While trastuzumab is well tolerated in general, the most important adverse effect is congestive heart failure (CHF). CHF occurred in less than 3% of the patients treated in the pivotal clinical trials, but the risk for trastuzumab-related CHF is likely higher in elderly patients who have pre-existing risk for CHF

Heikki Joensuu, MD, professor in the Department of Oncology at the Helsinki University Hospital and University of Helsinki in Finland

In all four large randomised trials that established the current standard treatment (chemotherapy plus trastuzumab), trastuzumab was given for one year and, therefore, the one-year duration became the standard, Joensuu explained. In two randomized trials with relatively limited statistical power, there was no statistical difference in DFS or OS between those who received nine weeks versus 12 months of trastuzumab.

 

 

The current standard treatment is lengthy, costly, and occasionally associated with cardiac adverse events. While trastuzumab is well tolerated in general, the most important adverse effect is congestive heart failure (CHF). CHF occurred in less than 3% of the patients treated in the pivotal clinical trials, but the risk for trastuzumab-related CHF is likely higher in elderly patients who have pre-existing risk for CHF

Heikki Joensuu, MD

Joensuu and colleagues studied whether it is sufficient to administer trastuzumab with chemotherapy only for a brief period of time (nine weeks) instead of the standard practice of administering trastuzumab both during chemotherapy (for nine weeks) and then as a single agent after stopping chemotherapy (for 12 months).

In SOLD, the investigators randomly assigned (1:1) 2,176 patients with early-stage HER2- positive breast cancer to the nine-week trastuzumab arm or the 12-month trastuzumab arm. Patients in both arms received three cycles of docetaxel (80 mg/m2 or 100 mg/m2 ) and trastuzumab three times a week, followed by three cycles of chemotherapy. Patients in the nineweek arm received no further treatment while those in the 12-month arm received trastuzumab every three weeks for 14 cycles. Patients with estrogen receptor-positive cancer received appropriate endocrine treatment and radiation therapy per guidelines.

In the 12-month arm, DFS was 90.5%, compared with 88% in the nine-week arm. There was no substantial difference in DDFS and OS between the two arms: five-year DDFS was 93.2% in the nine-week arm and 94.2% in the 12-month arm; five-year OS was 94.7% in the nine-week arm and 95.9% in the 12-month arm.

Among patients who received 100 mg/m2 docetaxel, DFS in the nine-week arm was similar to the DFS in the 12-month arm, but among those who received 80 mg/m2 docetaxel, 12 months of trastuzumab yielded superior DFS than nine weeks, suggesting that the dose of docetaxel administered with trastuzumab may influence survival outcomes.

A limitation of the study is that because of cancer characteristics and some logistical issues, including not being able to reach the planned number of DFS events within a reasonable time frame, the study had lower statistical power than planned.

SOLD was funded by Pharmac (New Zealand), Sanofi, Novartis, the Academy of Finland, the Cancer Society of Finland, Helsinki University Hospital research funds, Sigrid Juselius Foundation, and Jane and Aatos Erkko Foundation. Joensuu is a scientific advisor for Neutron Therapeutics, has received consultation fees from Orion Pharma, and has stock ownership interest in Orion Pharma, Faron Pharmaceuticals, and Sartar Therapeutics.